Iterum Therapeutics rises on patent wins, UTI drug launch progress

Iterum Therapeutics

19/09/2025 13:59

** Shares of Iterum Therapeutics ITRM.O rise 3.7% to 70 cents premarket

** ITRM launched its new oral antibiotic, ORLYNVAH, across select U.S. markets in August, with EVERSANA's dedicated sales team

** Co says physicians have begun writing prescriptions and interest is expanding beyond initial targets

** ITRM says it secured new intellectual property in two markets; China granted patent covering combination of sulopenem etzadroxil, probenecid and valproic acid, effective through March 2041

** Adds that Mexico issued patent for bilayer tablet of sulopenem etzadroxil and probenecid, effective through December 2039

** As of last close, ITRM stock down 61.6% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))